Company intelligence
Latigo Biotherapeutics, Inc.
Positioned to change the treatment paradigm of pain medicines
Biotechnology Research
Thousand Oaks, US
65 employees
1 public signals
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics (Nasdaq: LTGO) is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo’s lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain.
Verified activity
Signals from Latigo Biotherapeutics, Inc.
1 published signal